Can you escape your genetic inheritance, and do lifestyle changes actually make a difference? Daniel Cossins set out to ...

The drug may slow the progression of Alzheimer’s disease, but it doesn’t improve the symptoms. It’s also incredibly expensive ...

With several disease-modifying therapies available for transthyretin amyloid cardiomyopathy (ATTR-CM) -- and more waiting in the wings -- choosing one has become a new challenge, with softer endpoints ...

Well, currently we have three FDA approved therapies for the management of transthyretin cardiac amyloidosis, and two of those belong to the category of stabilizers and the one and the most recent one ...

Can obesity damage your brain? New research shows that excess fat may trigger inflammation, disrupt insulin signals, and ...

People who were diagnosed with Parkinson’s disease in their 80s had a higher likelihood of showing evidence of brain buildup of amyloid beta, a protein linked to cognitive decline in Alzheimer’s ...

Feedback is amazed to find that the audible vocalisations of the house mouse is all but unstudied in favour of the ultrasonic ...

Northwestern University professor Hande Ozdinler is hoping to change how ALS is treated, saying the disease is too complex ...

Acoramidis reduced the cumulative burden of cardiovascular outcomes at 30 months in patients with transthyretin amyloid ...

Trontinemab is a potential new Alzheimer’s drug made by drug company Roche. It's still in development, with a trial due to ...

Over time, transthyretin amyloidosis (ATTR) can damage the nerves, heart, and other organs. This may lead to complications like heart problems, nerve damage, and trouble with everyday bodily functions ...